


# FINAL PROGRAMME



**18<sup>th</sup>**  
ANNUAL  
CONFERENCE

UNIFYING MINDS  
**TRANSFORMING CARE**

17-19 October 2024  
Toronto, Canada

ILCA  
2024

## TABLE OF CONTENTS

Letter of Welcome	3
Registration	4
ILCA Annual Conference 2024 Programme	6
• Thursday, 17 October 2024	4
• Friday, 18 October 2024	9
• Saturday, 19 October 2024	12
ILCA Annual Conference Programme Committee	15
Floorplan	16
Practicalities	17
Sponsors, Media and other Partners	18
Ilca Industry Partners 2024	19
About ILCA	20
Industry Symposia	21

## LETTER OF WELCOME

Dear ILCA members, colleagues and friends,

I am delighted to welcome you to Toronto and the 18th Annual Conference of the International Liver Cancer Association which fittingly takes place in October - Liver Cancer Awareness month.

ILCA is a global, multidisciplinary community devoted to improving outcomes in liver cancer through research and education, and the Annual Conference fulfils a key role in this mission. Over the next few days, you will hear about the latest developments in clinical and fundamental research from international leaders in their fields. Hot topics will be debated, and challenging cases discussed in our tumour board. Your interaction and contributions are greatly encouraged.

Patient advocacy is becoming an increasingly important aspect of our work and will be the focus of a dedicated session exploring pathways to access treatment and addressing the needs African nations. Additionally, and in the spirit of cross society working, we are delighted to collaborate with CASL and AASLD in a joint session on prevention and surveillance.

This truly outstanding programme has been put together by our fantastic programme committee chaired by Amit Singal and with the wonderful support of the ILCA central office team. Finally, we are hugely grateful to our sponsors – without their support the conference would simply not be possible.

Treatment of liver cancer is evolving at pace, and the ILCA conference is a great place to share the excitement, energy and ideas that will continue to fuel progress over the coming years. Enjoy!

On Behalf of the ILCA Governing Board

**Tim Meyer**  
**ILCA President**



**Tim Meyer MD, PhD**  
ILCA President

A handwritten signature in black ink, appearing to read 'Tim Meyer'.



**Amit Singal, MD**  
ILCA Executive Secretary

A handwritten signature in black ink, appearing to read 'Amit Singal'.

## REGISTRATION

Registration must be completed online at [Registration – ILCALive](https://ilcalive.org)

ILCA members benefit from special registration fees. If you'd like to become a member, simply sign up today and benefit from the many advantages and join the ILCA community

Attendee Category	Super Early Bird (until 7 <sup>th</sup> of March)	Early Bird (until 31 <sup>st</sup> of May)	Regular Fee (until 16 <sup>th</sup> of October)	On-Site Fee (17 <sup>th</sup> to 19 <sup>th</sup> October)
ILCA Member	320	420	535	595
Non-Member	520	690	745	800
Student ILCA Member	165	180	215	240
Student Non-Member	206	227	265	290
Nurse / Pharmacist member	165	180	215	240
Nurse / Pharmacist non -member	206	227	265	290
Virtual only fee	258	280	370	370



**ILCA conference** INTERNATIONAL LIVER CANCER ANNUAL CONFERENCE 2024  
TORONTO • CANADA

**18<sup>th</sup> ANNUAL CONFERENCE ILCA 2024**  
UNIFYING MINDS  
TRANSFORMING CARE  
**17 – 19 October 2024**

For More Information – [ilcalive.org](https://ilcalive.org)

CO-LOCATED WITH:  
**CASLSTC 2024**  
2024 CASL SINGLE TOPIC CONFERENCE  
ON HEPATOCELLULAR CARCINOMA  
**19 – 20 October 2024**

We believe that by working together, we can extend the impact of our work worldwide and drive positive change in our field. That is why we offer special rates to encourage you to extend your stay in Toronto, attend both events and expand your knowledge even more!

Registration Type	Regular Registration Rate (ends October 4, 2024)	On-site Registration Rate (from October 5, 2024)
CASL & ILCA Member*	\$ 850.00	\$ 1,000.00
CASL Member - ILCA Non-Member*	\$ 1,100.00	\$ 1,250.00
Trainee	\$ 300.00	\$ 375.00
Nurse/Allied Healthcare Professional	\$ 380.00	\$ 450.00

\*Please contact [casl@hepatology.ca](mailto:casl@hepatology.ca) to obtain your member code

<https://www.caslstc.ca/stc2024>



## REGISTRATION

### VIRTUAL REGISTRATION: UNABLE TO JOIN US IN TORONTO?

Participate virtually in **ILCA24** and access sessions from the comfort of your own space.

Please note that the sessions are not live streamed, but with the Virtual Pass you will have access to the recordings which will be available 48 hours after the end of the Conference.



### VENUE & ACCOMMODATION

The venue for the ILCA 2024 Annual Conference is the **Hilton Hotel in Toronto.**

Please visit <https://ilcalive.org> for future information and for hotel reservations.

Through this website you can reserve, modify or cancel your reservations at any time and receive updated information about the event.

**We look forward to seeing you!**



[Get in touch!](#)



[Book your stay](#)

## SCIENTIFIC PROGRAMME

### DAY 1

THURSDAY 17<sup>TH</sup> OF OCTOBER 2024

11:00 – 11:05	<b>ILCA AC2024 Opening Ceremony</b> Tim Meyer, ILCA President, MD, PhD, (UK)
11:10 – 13:15	<b>Bench To Bedside: Emerging Therapeutic Targets</b>  <b>11.10 - 11.15</b> <b>Introduction from session chairs</b> Valerie Chew, MD, PhD (Singapore) and Tim Greten, MD (USA)  <b>11.15 - 11.30</b> <b>Metformin for the treatment of NASH - HCC</b> Tim Greten, MD (USA)  <b>11.30 - 11.45</b> <b>Anti - TIGIT for HCC</b> Carmen Wong, MD (Hong Kong)  <b>11.45 - 12.00</b> <b>Tumor associated macrophages via PI3K - gamma inhibition to enhance immunotherapy for HCC</b> Su Jong Yu, MD (Korea)  <b>12.00 - 12.15</b> <b>Metabolic reprogramming of CCA and therapeutic implications</b> Chiara Braconi, MD, PhD (UK)  <b>12.15 - 12.30</b> <b>Future of immunotherapy for liver cancer</b> Tak W. Mak, MD (Canada)  <b>12.30 - 12.45</b> <b>Cancer vaccines in hepatocellular carcinoma - is there a role among the immune oncology landscape?</b> Toh Han Chong, MD (Singapore)  <b>12.45 - 13.00</b> <b>Anti - GPC CAR - T cells in HCC</b> Mitchell Ho, PhD (USA)  <b>13.00 - 13.15</b> <b>Panel Discussion</b>
13:15 – 14:00	<b>Poster Tour &amp; Lunch Break</b> Location: Exhibition & Poster area Poster tour basic chairs: Valerie Chew, MD, PhD (Singapore) and Marco Sanduzzi, MD(Spain) Poster tour clinical chairs: Maria Reig, MD, PhD (Spain) and Nicole Rich, MD (USA)
14:00 – 14:30	<b>Clinical State of the Art</b> <b>Goals and endpoints in liver cancer clinical trials</b> Chair: Josep Maria Llovet, MD, PhD (Spain) Speaker: Bruno Sangro, MD, PhD (Spain)

## SCIENTIFIC PROGRAMME

DAY 1 - THURSDAY 17<sup>TH</sup> OF OCTOBER 2024

14:30 – 16:00	<p><b>General Session 1 – Molecular Pathogenesis, Cell Biology and Translational Research</b> 4 oral presentations from accepted abstracts and 8 poster blast presentations. Chairs: Daniela Sia, PhD (USA) and Carmen Wong, MD (Hong Kong)</p> <p>14:35 - 14:45 <b>O-01, Comprehensive analysis of patients with hepatocellular carcinoma treated with anti-PD-L1 plus anti-CTLA-4 with locoregional therapy</b>, Yuta Myojin, MD (USA)</p> <p>14:45 - 14:55 <b>O-02, Macrophage heterogeneity and reduced inflammatory potential in human hepatocellular carcinoma revealed by single cell and spatial transcriptomics</b>, Jawairia Atif, (USA)</p> <p>14:55 - 15:05 <b>O-03, Advancing next-generation immunotherapy for cholangiocarcinoma</b>, Mariana Yáñez, (Spain)</p> <p>15:05 - 15:15 <b>O-04, Immune checkpoint B7-H4 promotes cholangiocarcinoma growth via TGFβ-induced stromal remodeling, unveiling a novel targetable tumor-stroma axis</b>, Emily Bramel, (USA)</p> <p>15:15 - 15:25 <b>Questions &amp; Answers</b></p> <p><b>Poster blast</b> 8 selected poster presenters will introduce their poster in 3 minutes pitch.</p> <p>15:20 -15:23 <b>P-1, Depth of response (DpR) and duration of response (DoR) are associated with overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC): Exploratory analyses of IMbrave150</b>, Masatoshi Kudo, MD, PhD (Japan)</p> <p>15:23-15:26 <b>P-3, Using a combined index of methylated SEPT9 with existing tumor markers as a screening test for early-stage hepatocellular carcinoma</b>, Issei Saeki, MD, PhD (Japan)</p> <p>15:26-15:29 <b>P-9, Association Between Safety Net Hospitals and Treatment Delays in Hepatocellular Carcinoma</b>, Zach Whitham, MD (USA)</p> <p>15:29-15:32 <b>P-11, Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial</b>, Sung Hwan Lee, MD (South Korea)</p> <p>15:32-15:35 <b>P-12, Unveiling the role of unfolded protein response in hepatocellular carcinoma behavior in TP53 and CTNNB1 genetic backgrounds</b>, Stefany Infante, (Spain)</p> <p>15:35-15:38 <b>P-14, Modeling Hepatocellular Carcinoma by CRISPR Editing of Porcine Primary Hepatocytes</b>, Lobna Elkhadragey, MD (USA)</p> <p>15:38-15:41 <b>P-15, Extensive molecular profiling in Predicting Survival in patients with cholangiocarcinoma treated with Cisplatin/ gemcitabine plus durvalumab, a large real-life worldwide population</b>, Lorenza Rimassa, MD (Italy)</p> <p>15:41-16:00 <b>Questions &amp; Answers</b></p>
	<p><b>Coffee Break &amp; Networking</b> Location: Exhibition &amp; Poster area</p>

## SCIENTIFIC PROGRAMME

DAY 1 - THURSDAY 17<sup>TH</sup> OF OCTOBER 2024

16:30 – 17:30	<p><b>Management of Unresectable Liver Localized</b></p> <p><b>16:30 - 16:32</b> <b>Introduction from session chairs</b> Bruno Sangro, MD, PhD (Spain) and Joycelyn Lee, MD, PhD (Singapore)</p> <p><b>16.32 - 16.44</b> <b>The story of SIRT – Should recent efficacy data erase our memory of prior failed trials?</b> Riad Salem, MD (USA)</p> <p><b>16.44 - 16.56</b> <b>Immune modulation for BCLC B: combining ICI and transarterial treatments</b> Stephen Chan, MD, PhD, FAHA (Hong Kong)</p> <p><b>16.56 - 17.08</b> <b>Patient selection for LRT: How do you define TACE/TARE unsuitable in 2023?</b> Edward Kim, MD (USA)</p> <p><b>17.08 - 17.20</b> <b>What is the role for locoregional therapies in patients iCCA?</b> Marina Baretti, MD (USA)</p> <p><b>17.20 - 17.30</b> <b>Panel Discussion</b></p>
17:30 – 18:30	<p><b>Bayer Industry Symposium</b> (see programme page 21)</p>
18:30 – 19:30	<p><b>Y-ILCA Career Development Roundtables &amp; Welcome Reception</b> Session organised by the Y-ILCA Committee with the aim of helping young investigators improve their academic and research skills and broaden their academic network.</p> <p>2 roundtables with different topics, each with 2 senior experts from different geographical backgrounds that will interact with young investigators in small groups to explore the topic for an hour.</p> <p><b>RoundTable 1: Basic Science &amp; Translational Research</b> Valerie Chew, MD, PhD (Singapore) Chiara Braconi, MD, PhD (UK)</p> <ul style="list-style-type: none"> <li>How to get started with an academic career in basic science: choosing the right research niche.</li> <li>Strategies on study design &amp; finding a good mentor</li> <li>Tips on grant applications</li> <li>Translating your research to an early phase clinical trial</li> <li>Presenting basic science well</li> <li>Publishing in a high impact journal</li> <li>Leadership skills &amp; how to set up your own research group</li> <li>How to manage work/life balance and clinical work/research</li> </ul> <p><b>RoundTable 2: Clinical</b> Grainne O’Kane, MD (Canada) Marina Baretti, MD (USA)</p> <ul style="list-style-type: none"> <li>How to get started with a clinical academic career in liver cancer</li> <li>Choosing the right research area &amp; finding a good mentor</li> <li>How to get involved in clinical trials</li> <li>How to build international research networks</li> <li>Tips on grant applications &amp; publishing in a high impact journal</li> <li>How to manage clinical work and research</li> <li>Leadership skills &amp; how to set up your own research group</li> <li>Settlement of a multidisciplinary tumour board in your centre</li> </ul> <p><b>19.00 - 19.45</b> <b>ILCA AC2024 WELCOME RECEPTION</b> Join us for the welcome reception, where we will celebrate this year conference, connect with peers and thanks sponsors.</p>



## SCIENTIFIC PROGRAMME

### DAY 2

FRIDAY 18<sup>TH</sup> OF OCTOBER 2024

08.30 – 09.30	EISAI Breakfast Industry Symposium (breakfast available from 08:00) (see programme page 22)
09.30 – 10.30	<p><b>Translational Spotlight on CCA</b></p> <p><b>09.30 - 09.32</b> <b>Introduction from session chairs</b> Chiara Braconi, MD, PhD (UK) and Arndt Vogel, MD (Germany)</p> <p><b>09.32 - 09.44</b> <b>Overcoming Primary and Secondary Resistance to FGFR2 fusions</b> Anna Saborowski, MD (Germany)</p> <p><b>09.44 - 09.56</b> <b>Preclinical models of cholangiocarcinoma – what have we learned</b> Luke Boulter, MD (UK)</p> <p><b>09.56 - 10.08</b> <b>Molecular and Genomic Features of CCA: Implications for treatment</b> Chiara Braconi, MD, PhD (UK)</p> <p><b>10.08 - 10.20</b> <b>Liquid Biopsy epigenetic profiling for cancer subtyping</b> Jacob Berchuck, MD (USA)</p> <p><b>10.20 - 10.30</b> <b>Questions &amp; answers</b></p>
10.30 – 11.00	Coffee Break & Networking
11.00 – 11.30	<p><b>ILCA Advocacy</b> Chair: Bruno Sangro, MD, PhD (Spain)</p> <p><b>11.00 - 11.10</b> <b>The intricate pathways to access drug therapies in HCC</b> Manon Allaire, MD (France)</p> <p><b>11.10 - 11.20</b> <b>Needs from Patients in Central, Southern and West Africa</b> Adwoa Adjei - Nkansah, MD (Africa)</p> <p><b>11.20 - 11.30</b> <b>Early Phase Clinical Trials From the Patient Perspective,</b> Melinda Bachini, Patient Advocate (USA)</p>
11.30 – 12.00	<p><b>Presidential Address and Awards Ceremony</b> Nelson Fausto Award and Junior Investigator Awards. In this session the International Liver Cancer Association is going to recognize 4 individuals for their outstanding contributions to advancing liver cancer research, Junior Investigator Awards as well as recognize this year Nelson Fausto Award.</p>

## SCIENTIFIC PROGRAMME

DAY 2 - FRIDAY 18<sup>TH</sup> OF OCTOBER 2024

12.00 – 13.00	<p><b>General Session 2: Epidemiology, Staging and Prognosis</b>  <b>4 oral presentations</b> from ILCA AC24 accepted abstracts.  Chairs: Alejandro Forner, MD (Spain) and Bruno Sangro, MD, PhD (Spain)</p> <p>12:05 – 12:15  <b>O-5, Comparative analysis of listing criteria for hepatocellular carcinoma: Milan criteria versus Ontario criteria – A UNOS analysis</b>, Christian Magyar, MD (Canada)</p> <p>12:05 – 12:15  <b>O-6, Serial Trends in Overall Survival Rates of Hepatocellular Carcinoma by Etiology and Year of Diagnosis: A single center analysis of 15,707 Korean patients</b>, Jonggi Choi, MD (South Korea)</p> <p>12:15 – 12:25  <b>O-7, Widening Urban-Rural Disparities in Liver Cancer Deaths in the United States, 2008-2022</b>, Andrew Moon, MD (USA)</p> <p>12:25 – 12:35  <b>O-8, Attributable Deaths and Disability-adjusted Life Years of Liver Cancer in China and Worldwide: Profiles and Changing Trends</b>, Mengdi Cao (China)</p> <p>12.35 - 13.00  <b>Questions &amp; answers</b></p>
13.00 – 14.00	<p>Roche Industry Symposium (see programme page 23)</p> <p>Lunch Break</p>
14.00 – 15.00	<p><b>ILCA Debates</b>  <b>Introduction from session chairs</b>  Amit Singal, MD (USA) and David Pinato, MD, PhD (UK)</p> <p><b>Debate 1: Combination Therapy vs Sequential Therapy in intermediate stage-HCC</b>  Jordi Bruix, MD (Spain) and Katie Kelley, MD (USA)</p> <p><b>Debate 2: An RCT for HCC surveillance is necessary and feasible</b>  Maria Reig, MD, PhD (Spain) and Nicole Rich, MD (USA)</p>
15.00 – 16.00	<p><b>General Session 3: Surveillance and Diagnosis</b>  <b>4 oral presentations</b> from ILCA AC2024 accepted abstracts.  Chairs: Valérie Paradis, MD, PhD (France) and Laura Kulik, MD (USA)</p> <p>15:05 – 15:15  <b>O-9, Cost-Effectiveness of a Precision Hepatocellular Carcinoma Surveillance Strategy in Patients with Cirrhosi</b>, Neehar Parikh, MD, MS (USA)</p> <p>15:15 - 15:25  <b>O-10, Effectiveness of Mailed Outreach and Patient Navigation to Promote HCC Screening Process Completion: A Multi-Center Pragmatic Randomized Clinical Trial</b>  Amit Singal, MD (USA)</p> <p>15:25 – 15:35  <b>O-11, Gallbladder Polyps: Implications for Gallbladder Cancer in a Cohort of 218,418 patients</b>, Korosh Khalili, MD (Canada)</p> <p>15:35 – 15:45  <b>O-12, Prediction &amp; Monitoring of Post-Operative Liver Cancer Recurrence Using Cell-Free DNA</b>, Bianca Kirsh, (Canada)</p> <p>15:45 – 16:00  <b>Questions &amp; answers</b></p>

## SCIENTIFIC PROGRAMME

DAY 2 - FRIDAY 18<sup>TH</sup> OF OCTOBER 2024

16.00 – 16.15	Coffee Break & Networking
16.15 – 17.15	<p><b>Tumor Board</b> <b>Introduction from session chairs</b> Anjana Pillai, MD (USA) and Neehar Parikh, MD, MS (USA)</p> <p><b>Tumor board case 1: Peds tumor case</b> Experts: Peng Wu, MD (USA) and Blayne Sayed, MD, PhD (Canada)</p> <p><b>Tumor board case 2: Mixed HCC-CCA</b> Experts: Adam Yopp, MD (USA), David Pinato, MD, PhD (UK), Parissa Tabrizian, MD (USA) and Laura Kulik, MD (USA)</p> <p><b>Tumor board case 3: Borderline resectable HCC</b> Experts: Adam Yopp, MD (USA), David Pinato, MD, PhD (UK), Parissa Tabrizian, MD (USA) and Laura Kulik, MD (USA)</p>
17.15 – 18.15	AstraZeneca Industry Symposium (see programme page 23)
18.15 – 18.45	<p><b>Y-ILCA Masterclass – It's not all about writing: how to communicate science effectively</b> <b>Session organised by the Y-ILCA Committee with the aim of helping young investigators improve their academic and research skills and broaden their academic network.</b> Chairs: Sarah Cappuyns, MD, PhD (Belgium) and Joycelyn Lee, PhD (USA) Expert: Arndt Vogel, MD (Germany)</p>
18.45 – 19.30	General Assembly (ILCA members only)

## SCIENTIFIC PROGRAMME

### DAY 3

SATURDAY 19<sup>TH</sup> OF OCTOBER 2024

08:30 – 09:30	Guerbet Grant Session - TACE combined with ICI in uHCC : cross-overview (see programme page 25)
09:30 – 10:30	c-TACE combined with immunotherapy in unresectable HCC: myth or reality in 2024 ?
09:30 – 10:30	<p><b>Clinical Symposium – Comprehensive management of the patient: Beyond HCC-directed therapy</b>  <b>Introduction from session chairs</b>  Stephen Chan, MD, PhD, FAHA (Hong Kong) and Anand Kulkarni, MD, FACC (India)</p> <p>09.30 - 09.42  <b>Case presentation: Early stage/BCLC stage A HCC in an elderly with multiple comorbidities and weight loss + decision on ablation</b>, Adwoa Adjei-Nkansah, MD (Africa)</p> <p>09.42 - 09.54  <b>Evaluation of Fragility and Impact of Fragility on Treatment Outcome</b>, Puneeta Tandon, MD (Canada)</p> <p>09.54 - 10.06  <b>Role of nurse in patient's journey</b>, Neus Llarch (Spain)</p> <p>10.06 - 10.18  <b>Case Presentation: Worsening Condition</b>, Adwoa Adjei-Nkansah, MD (Africa)</p> <p>10.18 - 10.30  <b>Evidence-based Palliative care for HCC</b>, Hong Jae Chon, MD, PhD (South Korea)</p>
10:30 – 10:50	Coffee Break & Networking
10:50 – 11:20	<p><b>Basic State of the Art</b>  <b>AI in Medicine</b>  Chair: Tim Meyer, MD, PhD (UK)  Speaker: Mamatha Bhat MD, MSc, PhD, FRCPC (Canada)</p>
11:20 – 12:25	<p><b>General Session 4: Therapy &amp; Miscellaneous</b>  <b>4 oral presentations</b> from ILCA AC2024 accepted abstracts.  Chairs: Tim Meyer, MD, PhD (UK) and Katie Kelley, MD (USA)</p> <p>11:25 – 11:35  <b>0-13, Analysis by treatment period and baseline liver function in EMERALD-1: a Phase 3, randomized, placebo-controlled study of durvalumab with/without bevacizumab with TACE in participants with embolization-eligible unresectable hepatocellular carcinoma</b>, Stephen Chan, PhD (Hong Kong)</p> <p>11:35 – 11:45  <b>0-14, A novel glypican-3-targeted chimeric antibody-based gamma/delta TCR for treating liver cancer</b>, Dan Li, MD (USA)</p> <p>11:45 – 11:55  <b>0-15, Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: a large real-life worldwide population</b>, Lorenza Rimassa, PhD (Italy)</p> <p>11:55 – 12:05  <b>0-16, Pathological response following neoadjuvant immunotherapy predicts for relapse-free survival in hepatocellular carcinoma</b>, Antonio D'Alessio, MD (UK)</p> <p>12:05 - 12:15  <b>Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3</b>, Josep Maria Llovet, MD, PhD (Spain)</p> <p>12:15 – 12:25  <b>Questions &amp; answers</b></p>



## SCIENTIFIC PROGRAMME

DAY 3 - SATURDAY 19<sup>TH</sup> OF OCTOBER 2024

12.25 – 13.15	<p><b>Surgical resection: East meets West</b></p> <p><b>Introduction from session chairs</b> Gonzalo Sapisochin, MD, PhD, MSc (Canada) and Albert Chan, MD (Hong Kong)</p> <p>12:30 -12:40 <b>Advances in resection for liver cancer (HCC and CCA) and future of resectability in era of (neo)adjuvant therapies</b>, Osamu Itano, MD, PhD (Japan)</p> <p>12:40 - 12:50 <b>Role of (neo)adjuvant therapy for HCC (including TACE/TARE)</b>, Grainne O’Kane, MD (Canada)</p> <p>12:50-13:00 <b>Future of Resectability for HCC using (neo)adjuvant therapies</b>, Albert Chan, MD (Hong Kong)</p> <p>13:00 - 13:10 <b>Transplant for HCC and CCA, including IO prior to transplant</b>, Anjana Pillai, MD (USA)</p> <p>13:10-13:15 <b>Panel discussion</b></p>
13.15 – 14.15	<p><b>Merck Industry Symposium</b> (see programme page 24)</p> <p><b>Lunch Break &amp; Networking</b></p>
14.15 – 15.30	<p><b>ILCA, AASLD and CASL joint symposium: Prevention and Surveillance</b></p> <p>14.15 -14.17 <b>Introduction from session chairs</b>, Anjana Pillai, MD (USA) and Nicole Rich, MD (USA)</p> <p>14.17 - 14.29 <b>Strategies for HCC prevention, including in non-viral liver disease</b>, George Ioannou, MD (USA)</p> <p>14.29 - 14.41 <b>Emerging approaches to HCC surveillance</b>, Amit Singal, MD (USA)</p> <p>14.41 - 14.53 <b>Precision Surveillance: close to reality?</b> Nicole Rich, MD (USA)</p> <p>14.53 - 15.05 <b>Recall systems and linkage to care: Important steps after surveillance</b>, Maria Reig, MD, PhD (Spain)</p> <p>15.05 - 15.17 <b>System and population-level approaches to prevention and surveillance</b>, Jordan Feld, MD, MPH (Canada)</p> <p>15.17 - 15.30 <b>Questions &amp; Answers</b></p>
15:30 – 16:00	<p><b>Deep Dive on Clinical Trials</b></p> <p><b>Introduction from session chairs</b> Laura Kulik, MD, USA and David Pinato; MD, PhD, UK</p> <p><b>Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150</b> Daneng Li, MD, USA</p> <p><b>Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)</b> Lorenza Rimassa, MD, Italy</p>

## SCIENTIFIC PROGRAMME

DAY 3 - SATURDAY 19<sup>TH</sup> OF OCTOBER 2024

16.00 – 17.00	<b>Treatment Response Biomarkers</b>
	16.00 - 16.02
	<b>Introduction from session chairs</b> Maria Reig, MD, PhD (Spain) and Ju Dong Yang, MD (USA)
	16.02 - 16.14
	<b>Role of imaging for assessing treatment response?</b> Mishal Mendiratta-Lala, MD (USA)
	16.14 - 16.26
	<b>Application of AI in pathology for treatment response prediction</b> Julien Calderaro, MD (France)
17.00 – 17.10	16.26 - 16-38
	<b>Molecular-based prediction biomarkers in HCC: current status</b> Josep Maria Llovet, MD, PhD (Spain)
	16.38 - 16.50
	<b>Liquid biopsy for minimal residual disease in HCC</b> Augusto Villanueva, MD, PhD (USA)
	16.50 - 17.00
	<b>Questions &amp; answers</b>
17.00 – 17.10	<b>Closing Address</b>
	Tim Meyer, ILCA President, MD (UK)

## ILCA ANNUAL CONFERENCE PROGRAMME COMMITTEE

**A Big Thank You to the Members of ILCA AC2024 Programme Committee** for taking time out of their busy schedules to plan, organise and oversee the scientific programme. Their work and energy are making a difference at this year conference.



**Amit Singal**  
**Programme Committee Chair**  
USA



**Manon Allaire**  
France



**Stephen Chan**  
Hong Kong



**Valerie Chew**  
Singapore



**Antonio D'Alessio**  
UK



**Amaia Lujambio**  
USA



**Anjana Pillai**  
USA



**Maria Reig**  
Spain



**Gonzalo Sapisochin**  
Canada




**Augusto Villanueva**  
USA



**Arndt Vogel**  
Canada

## EXHIBITION FLOORPLAN



### Sponsors Booths:

- |                                       |                               |
|---------------------------------------|-------------------------------|
| 1. Booth 1: Eisai – Principal Sponsor | 6. Booth 6: Abbvie            |
| 2. Booth 2: Roche                     | 7. Booth 7: Bayer             |
| 3. Booth 3: Merck                     | 8. Booth 8: Boston Scientific |
| 4. Booth 4: AstraZeneca               | 9. Booth 9: Exact Science     |
| 5. Booth 5: Guerbet                   | 10. Booth 10: Fujifilm        |



## PRACTICALITIES

### About the Conference

The International Liver Cancer Association (ILCA) is the only international organization devoted exclusively to liver cancer research for experts from all related disciplines.

ILCA aims at creating an international multidisciplinary forum to address the increasing incidence of liver cancer through the enhancement of the knowledge of clinical, translational and basic research, creating novel preventive, diagnostic and therapeutic strategies.

The purpose for which ILCA was established is the advancement of medical education, research, and clinical care in the field of liver cancer.

Please visit us at the ILCA Hub. The ILCA Team will be pleased to meet you and provide you with any information you may wish to have on ILCA activities, membership and future conferences. More ILCA Information is also available at [www.ilca-online.org](http://www.ilca-online.org).

### Accreditation

The International Liver Cancer Association's 18th Annual Conference is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada and accredited by the Canadian Association for the Study of the Liver. **Participants can claim up to a maximum of 20 study credits.**

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at [www.ama-assn.org/go/internationalcme](http://www.ama-assn.org/go/internationalcme).

Meeting attendees who are specialist physicians may claim their credits directly online by visiting MAINPORT (<https://mainport.royalcollege.ca>) to record learning and outcomes.

### Junior Investigator Awards

ILCA will recognize extraordinary achievements in liver cancer research across disciplines and support the professional development of four junior investigators in training. The awards will be given for novel and significant liver cancer research across the fields of basic cancer research; translational cancer research; cancer diagnosis; the prevention of cancer; or cancer patients treatment.

The investigators who submit the best clinical oral and best poster presentations and the best basic-translational oral and best poster presentations will be honored LIVE on Friday, 18th October at 11.30 EDT (Eastern Daylight Time). Presidential Address and Awards Ceremony

### Official Language

The official language of the conference is English. Simultaneous translation will not be provided.

## THANK YOU TO OUR SPONSORS AND SUPPORTERS FOR THEIR SUPPORT

### ILCA 2024 PRINCIPAL SPONSOR



### ILCA 2024 CONFERENCE SPONSOR



### ILCA 2024 CONFERENCE SUPPORTERS



### ASSOCIATIONS & MEDIA PARTNERS



## ILCA INDUSTRY PARTNERS 2024



## TOGETHER FOR BETTER LIVER CANCER PATIENT TREATMENT AND CARE.

Liver cancer incidence rates are rapidly increasing across the world. And, because it is rarely detectable early, when it is most treatable, any liver cancer is difficult to cure.

Our industry partnership programme for 2024 offers healthcare companies the platform from which to support ILCA's mission and values through educational, scientific activities and events.

We offer a strategic forum for high-level dialogue between ILCA leadership and industry partners to discuss the key issues for the future of liver cancer treatment, as well as recognition of your year-round partnership support.



## ABOUT ILCA

Liver cancer is rapidly increasing worldwide, triggering widespread interest and strong focus surrounding all aspects of this disease. Given the naturally multidisciplinary nature of liver cancer, however, no single association has before the International Liver Cancer Association (ILCA) adopted a transversal approach to liver cancer by connecting expertise from interrelated fields, research and treatment levels. In response to this shortfall, ILCA was established in 2006 and is currently the only international organisation devoted exclusively to liver cancer across disciplines.

### Our Mission

ILCA strives to advance research in the pathogenesis, prevention, and treatment of liver cancer, by promoting novel pathogenic, diagnostic, and therapeutic interventions for liver cancer, and taking a transversal approach to research. Indeed, ILCA brings together scientists, physicians and allied professionals from all interrelated fields and countries and strives to welcome and incorporate individuals involved in all the scientific disciplines devoted to basic, translational and clinical research in liver cancer as individual members. ILCA actively partners with other professional associations involved in any aspect related to liver cancer research, with the objective to join efforts for the benefit of science.

### Joining Our Community

We invite you to discover more about ILCA on [www.ilca-online.org](http://www.ilca-online.org), as well as to connect with our expanding group of interested physicians, scientists, and allied health professionals from various fields and from around the world.

Membership to ILCA not only provides you with exclusive benefits such as reduced registration rates to our Annual Conferences, exciting networking and educational opportunities and active involvement in association affairs; it also helps us to develop our activities and our reach to advance liver cancer research and care.

### ILCA Governing Board

EXECUTIVE COMMITTEE	COUNCIL	GOVERNING BOARD ADVISORS
President: <b>Tim Meyer, UK</b>	Valerie Chew, Singapore	Alejandro Forner, Spain
Executive Secretary: <b>Amit Singal, USA</b>	Tim Greten, USA	Federico Piñeiro, Argentina
Treasurer: <b>Lorenza Rimassa, Italy</b>	R. Kate Kelley, USA	Marco Sanduzzi, Spain
Head of External Relations: <b>Stephen Chan, Honk Kong</b>	Valérie Paradis, France	Bruno Sangro, Spain
Past President: <b>Jessica Zucman-Rossi, France</b>	Neehar Parikh, USA	
	Anjana Pillai, USA	
	David Pinato, UK	
	Gonzalo Sapisochin, Canada	
	Daniela Sia, USA	
	Carmen Wong, Hong Kong	



## INDUSTRY SYMPOSIA



THURSDAY 17<sup>TH</sup> OCTOBER, 5:30–6:30PM

**Title:** Optimising MDT – Practical management strategies in HCC care

**Chair:** Amit G. Singal (Chair), MD, MS, Professor of Medicine

TOPIC	PRESENTERS
Introduction & current practice in HCC <ul style="list-style-type: none"><li>• Early Diagnosis</li><li>• How to integrate blood biomarkers</li><li>• How to integrate with imaging</li></ul>	Amit G. Singal
Early-Stage HCC: A Case Discussion <ul style="list-style-type: none"><li>• Imaging / novel blood biomarkers</li><li>• Surgery / interventional radiology</li></ul>	Bachir Taouli Gonzalo Sapisochin Amit G. Singal
Intermediate to Advanced Stage HCC <ul style="list-style-type: none"><li>• Perspective on the recent advances intermediate stage HCC</li><li>• Evolving role of systemic therapy in the int. and advanced stages</li><li>• Role of MDT in multimodality care</li></ul>	Josep M. Llovet Kartik S. Jhaveri Lorenza Rimassa, M.D
Closing	Arndt Vogel, MD

## INDUSTRY SYMPOSIA



### EISAI BREAKFAST INDUSTRY SYMPOSIUM

Friday, 18<sup>th</sup> October 2024, 08:30 – 09:30

**Title:** The re-emergence of TKIs in HCC: Current approaches and future advancements

#### Objectives

- Evaluate clinical and patient considerations impacting therapeutic decision making for patients with HCC
- Appraise primary endpoints from recent trials for HCC systemic therapies and clinical implications
- Understand the role of systemic therapy in the intermediate-stage setting and how this may affect multidisciplinary team management

#### Panel:

Chair:

**Sharlene Gill, MD, MPH, MBA, FRCPC, FASCO**

Professor of Medicine, University of British Columbia

Staff Oncologist, BC Cancer

Vancouver, British Columbia

Faculty:

**Arndt Vogel, MD, PhD**

Professor of Medicine, University of Toronto

Longo Family Chair in Liver Cancer Research

Toronto, Ontario

#### Program

TOPIC	PRESENTERS
Welcome and introduction	Sharlene Gill, MD
Current considerations for therapeutic decision making in advanced HCC	Sharlene Gill, MD
Critical appraisal of recent trial results for systemic therapies in advanced HCC	Arndt Vogel, MD
The role of systemic therapy for intermediate-stage HCC	Arndt Vogel, MD
Q&A and discussion	All faculty Facilitated by Sharlene Gill, MD

#### Abstract:

Join us for Eisai's Breakfast Symposium where leading experts will discuss the evolving role of TKI therapy in hepatocellular carcinoma (HCC), followed by an interactive Q&A.

Our experts will cover a variety of topics in HCC, including an evaluation of the considerations impacting therapeutic decision making in the advanced setting, an appraisal of the clinical implications of recent trial results, and a discussion on the emerging role of systemic therapy in the intermediate-stage setting.

#### Disclaimer:

Eisai Ltd has organised and funded this symposium.

This activity is intended for healthcare professionals only. Eisai products will be discussed.

#### Footer:

TKI, tyrosine kinase inhibitor.

## INDUSTRY SYMPOSIA



**Friday 18<sup>th</sup> October 2024; 13:00–14:00**

**Title:** Transforming liver cancer treatment: from today's innovation to tomorrow's potential

**Panel:**

Chair: Bruno Sangro

Faculty: Arndt Vogel, Gonzalo Sapisochi, Angela Lamarca

**Program**

TOPIC	PRESENTERS
Welcome and introduction	Bruno Sangro
Current treatment approaches for HCC: modern strategies	Arndt Vogel, Gonzalo Sapisochin
Innovative approaches to treating HCC – what lies ahead	Angela Lamarca, Gonzalo Sapisochin
Audience Q&A and panel discussion	Panel
Close	Bruno Sangro



**Friday, 18<sup>th</sup> October 2024, 5:15pm – 6:15pm**

**Title:** The dynamic landscape of HCC management: what is the future outlook for patients across the continuum?

**Program**

TOPIC	PRESENTERS
Welcome and introduction	Bruno Sangro
Examining treatment advances with immunotherapy for patients with advanced unresectable HCC	David Pinato
Case study discussion: Clinical decision-making in advanced unresectable HCC	Bruno Sangro
Reviewing the emergence of multimodal strategies for patients with earlier stages of HCC	Bruno Sangro, Gonzalo Sapisochin
Future outlook for patients across the HCC continuum	Gonzalo Sapisochin
Audience Q&A	All faculty

## INDUSTRY SYMPOSIA



**Saturday, 19<sup>th</sup> October, 1:15 -2:15 pm**

**Title:** Transforming care: Advancing hepatobiliary cancer care through multidisciplinary collaboration

**Panel:**

Chair:

**Jennifer Knox**

Medical Oncologist

Professor of Medicine

University of Toronto

Toronto, Ontario, Canada

Faculty:

**David Madoff**

Professor of Radiology, Medicine (Oncology) and Surgery  
(Oncology)

Vice Chair for Clinical Research

Academic Chief, Interventional Radiology

Department of Radiology and Biomedical Imaging

Yale School of Medicine

New Haven, Connecticut, USA

**Adam Yopp**

Professor of Surgery

Division Chief of Surgical Oncology

The University of Texas Southwestern Medical Center

Dallas, Texas, USA

**Arndt Vogel**

Professor of Medicine

University of Toronto

Longo Family Chair in Liver Cancer Research

Division of Gastroenterology and Hepatology

Toronto General Hospital

Medical Oncology, Princess Margaret Cancer Centre

Toronto General Hospital Research Institute

Schwartz Reisman Liver Research Centre

Toronto, Ontario, Canada

### Program

TOPIC	PRESENTERS
Welcome and introduction	Jennifer Knox
Case 1: Early-stage hepatocellular carcinoma	Adam Yopp, MDT panel
Case 2: Intermediate HCC	David Madoff, MDT panel
Case 3: Advanced/metastatic biliary tract cancer (BTC) patient	Arndt Vogel, MDT panel
Summary and close	Jennifer Knox

## ILCA 2024 GRANT SESSION

**Saturday, 19<sup>th</sup> October, 8:30 -9:30 pm**

**Title:** TACE combined with ICI in uHCC : cross-overview

**Faculty & Panelist:**

**Julius Chapiro**, MD/PhD - Yale School of Medicine. Yale, USA

**Lorenza Rimassa**, MD. Associate Professor of Medical Oncology, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy

**Terence P. Gade**, MD, PhD - PIGI Lab. Associate Professor of Radiology and Cancer Biology, Perelman School of Medicine at the University of Pennsylvania

**Program**

TOPIC	PRESENTERS
8:30 - 8:35: Opening	Julius Chapiro
8:35 - 8:47: Immunotherapy combined with LRT in uHCC: the oncologist perspective	Prof. Lorenza Rimassa
8:47 - 8:59: Immunotherapy associated with optimal c-TACE in uHCC: the IR perspective	Terence P. Gade
9:00 - 9:30: Tumor board discussion & Take away messages	Julius Chapiro, Bruno Sangro, Terence Gade, Lorenza Rimassa

Session supported by an unrestricted grant from:

**Guerbet** | 



JOIN THE **ILCA COMMUNITY** AND  
REGISTER FOR THE CONFERENCE.

**WE CAN'T WAIT TO SEE YOU IN TORONTO!**

## Contact Us

International Liver Cancer Association (ILCA)  
Avenue des arts, 47  
B-1000 Brussels – Belgium

Tel: +32 (0)2 320 2531  
Email: [info@ilca-online.org](mailto:info@ilca-online.org)  
Website: [www.ilca-online.org](http://www.ilca-online.org)